phase i-ii studi advanc head neck squamou cell carcinoma patient recombin human interferon gamma associ immunodefici head neck squamou cell carcinoma concept activ agent mean cancer activ immunolog messeng interferon gamma laboratori direct cytotox effect cultur squamou cell carcinoma head neck feasibl patient advanc resect head neck cancer agent phase i-ii trial recombin human interferon gamma infus weekli time studi tumor immunolog paramet treatment patient studi recombin human interferon gamma dose hour minim side effect patient measur respons stabil diseas progress treatment histopatholog result treatment similar vitro observ necrosi differenti tumor cell tumor mark decreas cellular chang tumor volum due extracellular keratin deposit studi evalu adopt immunotherapi trial head neck cancer paramet simpl tumor regress end point import lymphokine-induc chang further evalu recombin human interferon gamma agent human interferon gamma 